Summary
In a multicenter study we used a consensus protocol including more than five subsequent therapeutic steps for treatment of patients with advanced breast cancer. A total of 335 evaluable patients from 27 participating hospitals were allocated to a low- or high-risk group, receiving different therapies during the initial phase of treatment. About half of these patients were treated without protocol violations (compliers). The protocol non-compliers were divided into three groups: those receiving more intensive therapy than recommended, those with similarly intensive, and those with less intensive therapy. The reasons for protocol violations were analysed. The intensity of the therapy given actually was correlated with the survival of subgroups. Median survival times were significantly longer in 208 low-risk than in 127 high-risk patients (P<0.0001), marginally longer in 165 compliers than in 170 non-compliers (P<0.04), significantly longer in low-risk compliers than in low-risk non-compliers (P=0.002), and significantly shorter in high-risk compliers than in high-risk non-compliers (P=0.007). Survival of all subgroups of low-risk non-compliers was the same regardless of the actual therapies given. The survival of high-risk patients who received less intensive therapy was significantly longer than that of high-risk compliers (P=0.015). After six cycles of successful chemotherapy there was no difference, either in time to progresion or in survival, between patients who had received either maintenance therapy or no therapy. We postulate that the groups of low-risk and high-risk patients comprised patients with different prognoses. Among low-risk patients, survival of the subgroup with poor prognosis (low-risk non-compliers) was not influenced by therapy. Among high-risk patients, a subgroup with poor prognosis may have been overtreated by using standard chemotherapies as recommended in our consensus protocol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CAF:
-
cyclophosphamide, Adriblastin, 5-fluorouracil
- CMF:
-
cyclophosphamide, metothrexate, 5-fluorouracil
References
Allegra JC (1983) Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer. Sem Oncol 10 (suppl 2):23–28
Bull J, Tormey DC, Li SH, Carbone TP, Falkson G, Blom J, Perlin E, Simon R (1978) A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy. Cancer 41:1649–1657
Canellos GP (1987) Treatment of metastases. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast diseases. Lippincott, Philadelphia, pp 385–391
Canellos GB (1988) The dose dilemma. J Clin Oncol 6:1363–1364
Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC (1974) Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J 1:218–220
Canellos GP, Pocock SJ, Taylor SG, Sears ME, Klaasen DJ, Band PR (1976) Combination chemotherapy for metastatic breast carcinoma. Cancer 38:1882–1886
Hahnel R, Woodings T, Vivian AB (1979) Prognostic value of oestrogen receptors in primary breat cancer. Cancer 44:671–676
Henderson IC, Hayes DF, Gelman R (1988) Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6:1501–1515
Henderson K, Gelman R, Cavellos SP, Frei E (1981) Prolonged disease free survival in advanced breast cancer treated with super-CMF Adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep (suppl 1) 65:67–75
Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith RL, Blumenschein GR, Yap HY, Rodriguez V (1987) Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units. A prospecitive randomized study. J Clin Oncol 3:354–364
Howat JMT, Harris M, Swindell R, Barnes DM (1985) The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer 51:263–270
Howell A, Harland RNL, Bramwell VHC, Swindell R, Barnes DM, Redford J, Wilkinson MJS, Crowther D, Sellwood RA (1984) Steroid hormone receptors and survival after first relapse in breast cancer. Lancet I:588–591
Hryniuk WM (1988) More is better. J Clin Oncol 6:1365–1367
Hryniuk WM, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281–1288
Israel L, Brean JL, Aguilera J (1980) High-dose cytoxan and high-dose fluorouracil: a new first regime for advanced breast cancer. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 21:409
Moseley HS, Peetz ME, Keenan EJ, Awrich AE, Fletcher WS (1980) Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors. Am J Surg 140:164–172
Paterson AHG, Zuck VP, Szafran O, Lees AW, Hanson J (1982) Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin Oncol 18:937–943
Paterson AHS, Szafran O, Hanson J, Cyr M, Lees AW (1985) Response to treatment and its influence on survival in metastatic breast cancer. Am J Clin Oncol 8:283–292
Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockermann JP, Moore JO (1988) High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368–1376
Porzsolt F, Schreml W, Buchelt L, Meuret G, Mende S, Strigl P, Redenbacher M, Klumpp D, Schmelz M, Knöchelmann R, Hiemeyer V, Fleischer K, Kreuser ED, Leichtle R, Popp C, Kloiber R (1987) Konzept zur Behandlung metastasierender Mammakarzinome außerhalb von Universitätskliniken: Beschreibung der Methode und Prüfung der Effizienz. Onkologie 10:367–373
Possinger K, Wilmanns W (1986) AIO-Studien zur Behandlung des metastasierenden Mammakarzinoms. In: Nagel GA (ed) Mammakarzinome. Springer, Berlin Heidelberg New York Tokyo, pp 84–91
Rosner D, Nemoto T, Lange WW (1987) A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer. Cancer 59:874–883
Schreml W, Porzsolt F, Mende S, Buchelt L, Strigl P, Nessler A, Brass B (1985) Randomisierter Vergleich zwischen Beobachtung und Erhaltungstherapie nach Induktions-Chemotherapie bei metastasierendem Mammarkarzinom. Dtsch Ges Senol Hamburg
Stewart JF, King RJB, Sexton SA, Millis RR, Rubens RD, Hayward JL (1981) Oestrogen receptors, sites of metastatic disease and survival in current breast cancer. Eur J Cancer 17:449–453
Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562
Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D, Sutherland H (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherhapy for patients with metastatic breast cancer. J Clin Oncol 6:1377–1387
Tranum B, Hoogstraten B, Kennedy A, Vaughn CB, Samal B, Thigpen T, Rivkin S, Smith F, Palmer RL, Costanzi J, Tucker WG, Wilson H, Maloney TR (1978) Adriamycin in combination for the treatment of breast cancer. Cancer 41:2078–2083
Author information
Authors and Affiliations
Additional information
This study was supported in part by the Bundesministerium für Arbeit und Sozialordnung and by the German subsidiaries of Asta-Degussa, Ciba-Geigy, Cyanamid-Lederle, Farmitalia, Pharma-Leo, Rhone-Poulenc, Upjohn
Rights and permissions
About this article
Cite this article
Porzsolt, F., Meuret, G., Kreuser, E.D. et al. Compliance of physicians and patients with a consensus protocol for treatment of advanced breast cancer. J Cancer Res Clin Oncol 115, 564–570 (1989). https://doi.org/10.1007/BF00391359
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00391359